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AbstrAct
FOXP2 shares partially overlapping normal tissue expression and functionality 
with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and 
marker of poor prognosis. FOXP2 is expressed in the plasma cell malignancy multiple 
myeloma but has not been studied in DLBCL, where a poor prognosis activated B-cell 
(ABC)-like subtype display partially blocked plasma cell differentiation. FOXP2 protein 
expression was detected in ABC-DLBCL cell lines, and in primary DLBCL samples tumoral 
FOXP2 protein expression was detected in both germinal center B-cell-like (GCB) and 
non-GCB DLBCL. In biopsies from DLBCL patients treated with immunochemotherapy 
(R-CHOP), ≥ 20% nuclear tumoral FOXP2-positivity (n = 24/158) correlated with 
significantly inferior overall survival (OS: P = 0.0017) and progression-free survival 
(PFS: P = 0.0096). This remained significant in multivariate analysis against either 
the international prognostic index score or the non-GCB DLBCL phenotype (P < 0.05 
for both OS and PFS). Expression of BLIMP1, a marker of plasmacytic differentiation 
that is commonly inactivated in ABC-DLBCL, did not correlate with patient outcome or 
FOXP2 expression in this series. Increased frequency of FOXP2 expression significantly 
correlated with FOXP1-positivity (P = 0.0187), and FOXP1 co-immunoprecipitated 
FOXP2 from ABC-DLBCL cells indicating that these proteins can co-localize in a multi-
protein complex. FOXP2-positive DLBCL had reduced expression of HIP1R (P = 0.0348),  
which is directly repressed by FOXP1, and exhibited distinct patterns of gene 
expression. Specifically in ABC-DLBCL these were associated with lower expression 
of immune response and T-cell receptor signaling pathways. Further studies are 
warranted to investigate the potential functional cooperativity between FOXP1 and 
FOXP2 in repressing immune responses during the pathogenesis of high-risk DLBCL.
IntroductIon
Diffuse large B-cell lymphoma (DLBCL) is the 
most common subtype of non-Hodgkin’s lymphoma 
and displays considerable heterogeneity in its genetics, 
clinical features and biology. Early attempts to identify 
DLBCL subtypes, such as the Kiel classification, 
distinguished categories based on tumor cell morphology 
as being either centroblastic or immunoblastic, the latter 
being associated with inferior outcome and sometimes 
showing plasmablastic or plasmacytoid features [1–4]. 
Subsequent gene expression profiling (GEP) also 
identified DLBCL subtypes with distinct cell-of-origin 
(COO) profiles, DLBCL with a germinal center B-cell-
like signature (GCB-DLBCL) having a better clinical 
outcome than those with an activated B-cell-like 
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(ABC-DLBCL) phenotype [5]. However, ABC-DLBCL 
is not a homogeneous category and reflects a spectrum 
of plasmablastic B-cell differentiation towards a 
terminally differentiated plasma cell phenotype. Indeed 
partial plasma cell differentiation within ABC-DLBCL 
has been proposed as a mechanism for loss of major 
histocompatibility complex class II expression in DLBCL 
[6], which correlates with significantly reduced survival 
[7, 8]. The aggressive clinical behavior of large B-cell 
lymphomas with plasmablastic differentiation presents 
a particular therapeutic challenge [9], highlighting the 
importance of improving our understanding of their 
underlying disease biology to identify new therapeutic 
opportunities. 
The transcription factor B lymphocyte-induced 
maturation protein 1 (BLIMP1)/PR domain containing 
1 with zinc finger domain (PRDM1) promotes the 
terminal differentiation of germinal center (GC) B cells 
into plasma cells [10–12]. In the B-cell lineage it is 
expressed specifically in a subset of GC centrocytes 
with plasmacytoid markers and in plasma cells [13, 14]. 
BLIMP1 acts primarily as a transcriptional repressor to 
extinguish the mature B-cell expression program [15], 
including the expression of GCB-DLBCL-associated 
genes such as LMO2 and HGAL [16]. BLIMP1 is 
specifically inactivated by structural alterations in the 
ABC-DLBCL subtype (24%). Many more non-GCB 
DLBCL tumors (77%) lack BLIMP1 protein expression, 
indicating that a block in post-GC cell differentiation 
could contribute to ABC-DLBCL pathogenesis [17]. 
Chromosome translocations driving expression of the 
BCL6 transcription factor were subsequently identified 
as an additional mechanism enabling transcriptional 
repression of BLIMP1 in ABC-DLBCL [18]. Studies of 
mouse models with inactivated Blimp1 have confirmed its 
function as a DLBCL tumor suppressor with a causal role 
in the pathogenesis of ABC-DLBCL [18, 19].
Forkhead box proteins are an evolutionarily 
conserved family of transcription factors with a wide 
range of critical biological functions and disease 
associations, including cellular differentiation [20]. 
FOXP1 has been identified as an ABC-DLBCL marker 
[15], whose expression correlated with poor clinical 
outcome in both CHOP [21, 22] and R-CHOP [23, 24] 
treated DLBCL patients. FOXP1 has been included 
in multiple immunohistochemical DLBCL subtyping 
algorithms aiming to distinguish DLBCL based on their 
COO phenotype [25–28]. In DLBCL, FOXP1 has been 
reported to promote B-cell proliferation [29], regulate 
genes involved in the germinal center reaction [30], repress 
the transcription of proapoptotic genes and cooperate with 
NF- κB to promote B-cell survival [31, 32], to potentiate 
WNT signaling [33], and to repress immune response 
signatures and MHC class II genes [32, 34]. While FOXP1 
protein expression is differentially expressed in normal 
B cells, it is absent from most normal and malignant plasma 
cells [35]. More recently FOXP1 has been shown to 
suppress plasma cell differentiation and thus may also 
functionally contribute to the block of terminal B-cell 
differentiation in DLBCL [36].
The FOXP family (FOXP1-4) is somewhat atypical 
in having a zinc finger and leucine zipper domain 
enabling both homo- and hetero-dimer formation [37]. 
Partially overlapping expression patterns and phenotypes, 
particularly of FOXP1 and FOXP2 in neurodevelopment 
and cognitive disorders [38] and in the lung [39–41], 
have indicated that these molecules have both shared 
and distinct biological functions. Furthermore, specific 
combinations of FOXP1/2/4 dimers are able to 
differentially fine-tune the expression of individual genes 
involved in the WNT and Notch pathways [42], which 
are both implicated in DLBCL pathogenesis. Existing 
data suggest that FOXP1 and FOXP2 generally show 
reciprocal patterns of expression during terminal B-cell 
differentiation and in B-cell malignancies. FOXP2 being 
absent in normal B cells and most B-cell lymphoma 
cell lines while being expressed in a subpopulation of 
normal plasma cells and in plasma cell dyscrasias, such 
as monoclonal gammopathy of undetermined significance 
(MGUS) and myeloma [43]. 
As DLBCL represents a spectrum of plasmablastic 
differentiation and a block in this process is causally 
involved in disease pathogenesis, we were interested 
to observe strong FOXP1 and FOXP2 co-expression in 
the ABC-DLBCL cell line OCI-Ly10 [43]. This, and the 
expression of FOXP2 in MGUS and myeloma, raised 
the possibility that FOXP2, like FOXP1, might also be 
involved in DLBCL pathogenesis. Furthermore, if these 
transcription factors were co-expressed in DLBCL tumor 
cells, there might be a physical and functional FOXP1-
FOXP2 interaction. Here we present the first study of 
FOXP2 expression in primary DLBCL, its relationship 
with COO subtypes, FOXP1, other molecules involved 
in B-cell differentiation and clinicopathological data. 
The poor clinical outcome associated with FOXP2 
expression in DLBCL together with its co-expression 
and co-immunoprecipitation with FOXP1 indicates that 
further studies are warranted to understand their potential 
cooperativity and contribution to DLBCL pathogenesis. 
rEsuLts
FoXP2 expression in dLbcL cell lines
Our prior study of FOXP2 expression in cell 
lines derived from lymphoid malignancies detected 
expression primarily in multiple myeloma and Hodgkin’s 
lymphoma [43]. However, the ABC-DLBCL cell line 
OCI-Ly10 also showed comparable FOXP2 protein and 
transcript levels to those in myeloma and Hodgkin’s 
lymphoma lines [43]. Western blotting and qRT-PCR 
(Figure 1A–1B) across an extended panel of eleven 
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DLBCL cell lines identified the ABC-DLBCL cell 
lines RIVA and SU-DHL-2 as also being strongly 
FOXP2-positive, with levels comparable to that in the 
myeloma cell line JJN3. Some nuclear FOXP2 protein 
expression was also detectable in SU-DHL-9 and much 
weaker expression in the cell lines OCI-Ly3 and RCK8 
(the latter only when blots were overexposed), all of 
which are ABC-DLBCL. OCI-Ly3 exhibited comparable 
transcript levels to the cell lines with abundant FOXP2 
protein expression, suggesting the differential detection 
of FOXP2 isoforms (e.g. FOXP2 proteins lacking the 
N-terminal FOXP2-73A/8 antibody epitope may be 
expressed) or that posttranscriptional mechanisms may 
restrict FOXP2 protein expression in this cell line. Thus 
3/7 ABC-DLBCL cell lines strongly expressed FOXP2 
(OCI-Ly10, RIVA and SU-DHL-2), while a further 3/7 
were weakly FOXP2-positive (SU-DHL-9, OCI-Ly3 and 
RCK8). Immunohistochemistry confirmed predominantly 
nuclear FOXP2 protein expression and a minority of 
positive nuclei in RCK8 and OCI-Ly3 was consistent 
with weak expression detectable by blotting (Figure 1C). 
None of five GCB-DLBCL cell lines exhibited detectable 
FOXP2 nuclear protein expression, although MIEU did 
express FOXP2 transcripts (Figure 1B).
Primary dLbcL patients with FoXP2-positive 
tumors have a poor clinical outcome
Given the expression of FOXP2 in myeloma [43] 
and in the majority of ABC-DLBCL cell lines, we 
investigated whether it might be a potential marker of 
plasma cell differentiation in DLBCL. BLIMP1 expression 
was also analyzed in the same series to determine whether 
FOXP2 had any relationship with this established marker 
of plasma cell differentiation. We analyzed both the 
frequency and intensity of tumoral nuclear FOXP2 and 
BLIMP1 protein expression in 158 primary DLBCL 
using immunohistochemistry. DLBCL tumors exhibiting 
variable intensity and frequency of FOXP2 expression 
are illustrated in Figure 2A. The frequency of expression 
of both proteins exhibited a non-Gaussian distribution: 
FOXP2 (P < 0.0001); BLIMP1 (P = 0.0029) (Figure 2B). 
Nuclear FOXP2 expression was detectable in 
49/158 (31%) of the DLBCL patients (Figure 2), the 
median frequency being 0% and the mean frequency being 
10%. No frequency threshold for FOXP2 expression had 
been previously defined in DLBCL, hence we tested the 
clinical relevance of 10% thresholds and selected ≥ 20% 
positivity, which identified 24 FOXP2-positive patients 
(15%). DLBCL patients with ≥ 20% nuclear FOXP2-
positivity exhibited significantly inferior overall survival 
(OS: P = 0.0017) and progression free survival (PFS: 
P = 0.0096) (Figure 2C–2D). The qualitative intensity of 
FOXP2 expression (score 0–1 versus 2–3) also identified 
a subgroup of DLBCL patients (n = 15) with poor clinical 
outcome (OS, P = 0.0027; PFS, P = 0.0093) (Figure 2E–2F). 
The median frequency of BLIMP1 protein expression 
in this DLBCL series was 10% and the mean was 19%. 
A variety of BLIMP1 thresholds (e.g. 10–30%) have been 
used for correlation with clinical outcome. Here we selected 
a ≥ 40% cut-off, as there was a trend towards an association 
with inferior OS (P = 0.0551, Figure 2G) that was not 
observed at lower thresholds. No association with PFS 
was observed at ≥ 40% cut-off (P = 0.1748, Figure 2H), 
and the qualitative intensity of BLIMP1 expression had no 
clinical relevance in this series (data not shown).
FoXP2 is a risk factor independent of either IPI 
or dLbcL coo in multivariate analyses
Frequency-defined FOXP2 and BLIMP1 categories 
were independent of patients’ clinical characteristics such 
as age, sex, performance status, the number of extranodal 
sites and their International Prognostic Index (IPI) risk 
group (Table 1). In multivariate analyses (Table 2), 
DLBCL patients with ≥ 20% FOXP2 expression exhibited 
significantly inferior outcome independent of either a high 
IPI score (OS: P = 0.0119; PFS: P = 0.0451) or non-GCB 
DLBCL subtype according to Hans (OS: P = 0.0047; PFS: 
P = 0.0186), Choi (OS: P = 0.0059; PFS: P = 0.0258) and 
Visco-Young (OS: P = 0.0098; PFS: P = 0.0367) algorithms. 
FoXP2 expression does not correlate with 
DLBCL COO subtype and identifies high-risk 
Gcb and non-Gcb dLbcL patients
GCB or non-GCB COO subtyping had already been 
demonstrated to define clinically relevant subgroups in 
this DLBCL series [23]. The frequency of FOXP2 protein 
expression exhibited no relationship with DLBCL COO 
subtype, defined using three (Hans, Choi and Visco-Young) 
immunohistochemical algorithms (Table 1, Figure 3A). 
In contrast, non-GCB DLBCL defined by two of the three 
COO algorithms exhibited elevated BLIMP1 expression, 
using either a 40% cut-off (Table 1: Hans P = 0.0044; Choi 
P = 0.0159) or 10% frequency increments (Figure 3B: 
Hans P = 0.0022; Choi P = 0.0490). DLBCL subtypes 
defined using the Visco-Young algorithm showed no 
relationship with BLIMP1 expression (Table 1, Figure 3B). 
The FOXP2 or BLIMP1 intensity scores exhibited no 
relationship with DLBCL COO subtype (data not shown).
Increased frequency of FOXP2 expression identified 
patients with significantly inferior OS in both the GCB 
(P = 0.0331) and non-GCB (P = 0.0475) subgroups of 
DLBCL patients (Figure 3C–3D). There was also a trend 
towards inferior PFS in both the GCB (P = 0.0987) and 
non-GCB (P = 0.0873) DLBCL subgroups that did not 
reach statistical significance (Figure 3E–3F). FOXP2 
expression was not clinically relevant in low (0–2) 
versus high (3–5) risk IPI subgroups of DLBCL patients 
(data not shown).
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Figure 1: FOXP2 is expressed in ABC-DLBCL cell lines. (A) Western blotting of nuclear lysates from GCB-DLBCL, ABC-DLBCL 
and myeloma cell lines with anti-FOXP2 (clone 73A/8) and anti-NPM (clone NA24) antibodies. An overexposed image (middle panel) shows 
very weak FOXP2 expression in OCI-Ly3 and just detectable expression in RCK8. *Indicates an upper band that is thought to be non-specific. 
MIEU remained negative in other experiments with more abundant sample loading. (b) qRT-PCR for FOXP2 transcripts in GCB- and ABC-
DLBCL cell lines. FOXP2 expression was normalized according to the expression of 18S rRNA housekeeping gene and expressed relative to 
JJN3 (set to 100%). (c) Immunohistochemical labeling of FOXP2 nuclear expression in DLBCL cell lines: showing negative (Karpas 422), 
weak (OCI-Ly3, RCK8) and strongly positive (OCI-Ly10, RIVA, SU-DHL-2) examples. Higher power insets are shown in the bottom right 
corners of each panel.
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Figure 2: FOXP2 expression confers inferior survival in R-CHOP-treated DLBCL cases. (A) Immunohistochemical 
labeling of FOXP2 expression in primary DLBCL cases with variable intensity and frequency of expression. Left to right these were scored 
as negative, intensity 1/frequency 55%, intensity 2/frequency 80%, intensity 3/frequency 100%. (b) Frequency distribution of FOXP2 
(left panel) and BLIMP1 (right panel) at each 10% cut-off level in DLBCL cases (n = 158). (c–H) Overall survival (OS) and progression 
free survival (PFS) of DLBCL cases (n = 158) according to FOXP2 frequency at 20% cut-off (C–D) or intensity (E–F), and BLIMP1 
frequency at 40% cut-off (G–H).
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FOXP1 and FOXP2 are co-expressed in high-
risk dLbcL and can be co-immunoprecipitated 
in Abc-dLbcL cells
While FOXP2 expression did not correlate with 
DLBCL COO subtype, this did not exclude the possibility 
of there being relationships between FOXP2 and 
individual molecules involved in B-cell differentiation. 
These potential relationships were investigated by 
comparing both categorical (defined by threshold of 
expression) and continuous variables (frequency in 10% 
increments) (Tables 3 and 4, respectively). FOXP2-
positivity (≥ 20%) correlated with reduced expression 
(≤ 10%) of the direct FOXP1 target HIP1R (P = 0.0348) 
and increased expression of MUM1/IRF4 (P = 0.0075). 
MUM1/IRF4 was the only marker that correlated with 
FOXP2 as both a categorical and continuous variable 
(P = 0.0476). There was no correlation between FOXP2 
Table 1: Clinical and hematologic characteristics of DLBCL patients stratified according to FOXP2 
and BLIMP1 expression
characteristics All cases (n = 158)
FoXP2 < 20%
(n = 134)
FoXP2 
≥ 20% 
(n = 24)
P-value
BLIMP1 
< 40%
(n = 130)
BLIMP1 
≥ 40% 
(n = 28)
P-value
Age (years)
 Median 67 67 72 0.4519 67 69 0.4930
 Range 20–91 20–91 58–87 20–91 44–90
sex
 Female (%) 70 60 (38) 10 (6) 0.7773 57 (36) 13 (8) 0.8034
 Male (%) 88 74 (47) 14 (9) 73 (46) 15 (9)
Stage
 I–II (%) 86 74 (47) 12 (8) 0.6360 73 (46) 13 (8) 0.3488
 III–IV (%) 72 60 (38) 12 (8) 57 (36) 15 (9)
Performance status
 0–1 (%) 136 117 (74) 19 (12) 0.2884 113 (72) 23 (15) 0.5076
 ≥ 2 (%) 22 17 (11) 5 (3) 17 (11) 5 (3)
LDH
 < ULN (%) 94 82 (52) 12 (8) 0.3037 80 (51) 14 (9) 0.2592
 ≥ ULN (%) 64 52 (33) 12 (8) 50 (32) 14 (9)
Extranodal sites
 0–1 (%) 133 113 (72) 20 (13) 0.9025 110 (70) 23 (15) 0.7447
 ≥ 2 (%) 25 21 (13) 4 (3) 20 (13) 5 (3)
IPI
 0–2 (%) 111 98 (62) 13 (8) 0.0612 93 (59) 18 (11) 0.4463
 3–5 (%) 47 36 (23) 11 (7) 37 (23) 10 (6)
COO (Hans)
 GCB (%) 89 78 (49) 11 (7) 0.2603 80 (51) 9 (6) 0.0044
 Non-GCB (%) 69 56 (35) 13 (8) 50 (32) 19 (12)
coo (choi; n = 155)*
 GCB (%) 95 83 (54) 12 (8) 0.2167 84 (54) 11 (7) 0.0159
 Non-GCB (%) 60 48 (31) 12 (8) 44 (28) 16 (10)
COO (Visco- Young; n = 157)†
 GCB (%) 98 87 (55) 11 (7) 0.0683 85 (54) 13 (8) 0.0924
 Non-GCB (%) 79 46 (29) 13 (8) 45 (29) 14 (9)
*Three cases (of 158) could not be classified for COO according to Choi algorithm; †One case (of 158) could not be classified 
for COO according to Visco-Young algorithm; ULN: Upper limit of normal.
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and BLIMP1 as either continuous (P = 0.1727) or 
categorical (P = 0.3820) variables.
No significant correlation was identified between 
the frequency of FOXP2 expression and that of its family 
member FOXP1 as continuous variables (Figure 4A, 
Table 4). However, of the 24 DLBCL patients with ≥ 
20% FOXP2 expression, only 5 exhibited < 70% FOXP1 
expression and a significant enrichment of FOXP2-
positive DLBCL (≥ 20% FOXP2 positivity) within the 
FOXP1-positive category (≥ 70% FOXP1) was observed 
(P = 0.0187; Table 3). The frequency of FOXP2 expression 
was also higher in DLBCL with a FOXP1hiHIP1Rlo 
phenotype (DLBCL with FOXP1 short isoforms potentially 
capable of transcriptionally repressing its direct target 
gene HIP1R) than those with FOXP1lo/HIP1Rhi expression 
(P = 0.0162: Figure 4B). Patients with a FOXP1hiHIP1Rlo 
phenotype were previously reported in both GCB and non-
GCB subtypes and exhibited significantly inferior survival 
in this series [23].
Twelve tumors displayed ≥ 50% frequency of 
expression of both transcription factors, indicating that 
FOXP1 and FOXP2 can be co-expressed at the single-cell 
level in a subset of primary DLBCL. Immunoprecipitation 
of FOXP1 from the ABC-DLBCL cell lines RIVA and 
SU-DHL-2, that have robust expression of both FOXP1 
and FOXP2, co-immunoprecipitated FOXP2 (Figure 
4C–4D). These data demonstrate that FOXP1 and FOXP2 
exist in a multi-protein complex and could potentially 
heterodimerize in ABC-DLBCL cells. The 45 DLBCL 
tumors with any frequency of FOXP1 and FOXP2 co-
expression exhibited significantly inferior OS (P = 0.0251) 
and a trend towards inferior PFS (P = 0.0759) (Figure 
4E–4F). Nineteen patients exhibited ≥ 70% FOXP1 and 
≥ 20% FOXP2 expression. These also exhibited significantly 
inferior OS (P = 0.0302) and a trend towards inferior PFS 
(P = 0.0797) when compared to those patients (n = 138) 
that lacked FOXP1/FOXP2 co-expression (Figure 4G–4H).
dLbcL tumors with FoXP2 protein expression 
have distinct gene expression profiles
To investigate the molecular mechanisms by which 
FOXP2 expression might contribute to aggressive disease 
and thus a poor clinical outcome, we compared the gene 
expression profiles of DLBCL patients with (n = 11) 
and without (n = 28) FOXP2 protein expression using 
an existing gene expression dataset (GSE31312) that 
was available for a subset of patients from this cohort 
(Figure 5A; Table S1). This analysis identified distinct 
genes whose up- or down-regulation distinguished 
FOXP2-positive versus -negative DLBCL. Upregulated 
genes included FOXP2 itself, identifying the microarray 
probe (1555516_at) that most significantly correlated 
with FOXP2 protein expression in these samples 
(P < 0.0001). One of the most downregulated genes, 
HIP1R, is a known directly FOXP1 repressed gene [23] 
and HIP1R protein exhibited an inverse relationship 
with FOXP2 in the current study. Subdividing patients 
into microarray-defined GCB-DLBCL or ABC-DLBCL 
subgroups showed different genes associated with FOXP2-
positivity (Figure 5B–5C; Table S1), with no overlap in the 
individual top 20 up- and down-regulated genes between 
GCB-DLBCL and ABC-DLBCL subgroups.
Gene ontology (GO) analysis was performed to 
determine the biological pathways associated with FOXP2 
protein expression in DLBCL (Figure 6A, Table S2). 
Analysis of the top 100 genes from all 39 DLBCL 
patients identified three significantly differentially 
represented GO terms inversely-associated with the 
presence of FOXP2 expression: regulation of cellular 
component organization, clathrin coat assembly and 
cellular component morphogenesis, with the DAB2 and 
SNAP91 genes being common to all three pathways. 
Although not represented in these pathways, HIP1R is 
already known to be functionally involved in clathrin 
Table 2: Multivariate analysis for OS and PFS in DLBCL patients treated with R-CHOP
risk Factor
os PFs
95% CI Hazard Ratio P-value 95% CI Hazard Ratio P-value
IPI ≥ 3 1.67–4.73 2.81 0.0001 1.82–4.83 2.97 < 0.0001
FOXP2 ≥ 20% 1.18–3.87 2.14 0.0119 1.01–3.23 1.81 0.0451
Non-GCB phenotype (Hans algorithm) 0.99–2.79 1.66 0.0539 0.98–2.55 1.58 0.0616
FOXP2 ≥ 20% 1.30–4.22 2.34 0.0047 1.12–3.56 2.00 0.0186
Non-GCB phenotype (Choi algorithm) 1.05–2.94 1.75 0.0323 1.06–2.76 1.71 0.0292
FOXP2 ≥ 20% 1.27–4.15 2.30 0.0059 1.08–3.45 1.93 0.0258
Non-GCB phenotype (Visco-Young 
algorithm) 1.16–3.31 1.96 0.0118 1.19–3.14 1.93 0.0079
FOXP2 ≥ 20% 1.21–4.00 2.20 0.0098 1.04–3.34 1.86 0.0367
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Figure 3: FOXP2 expression is not associated with non-GCB DLBCL primary cases, and it confers worse OS in 
GCB or non-GCB DLBCL subtypes. (A–b) Relationship of FOXP2 (A) or BLIMP1 (B) protein expression frequency with GCB or 
non-GCB DLBCL subtype according to Hans (n = 158), Choi (n = 155) or Visco-Young (n = 157) immunohistochemical algorithms. (c–F) 
OS (C–D) and PFS (E–F) in GCB-DLBCL (n = 89) or non-GCB DLBCL (n = 69) according to FOXP2 20% cut-off. The DLBCL cases 
were stratified according to Hans algorithm.
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Figure 4: FOXP2 is co-immunoprecipitated by FOXP1 and their co-expression confers worse survival in R-CHOP-
treated DLBCL cases. (A) Correlation of FOXP1 and FOXP2 expression frequency in DLBCL (n = 157). (b) Relationship 
of FOXP2 frequency with FOXP1hi/HIP1Rlo (n = 36), FOXP1lo/HIP1Rhi (n = 58) or non-reciprocal (n = 62) DLBCL cases. 
(c–d) Co-immunoprecipitation of endogenous FOXP1 in RIVA and SU-DHL-2 cell lysates with anti-FOXP1 JC12 antibody or with non-
specific IgG2a isotype and 130/B4 (“in house” anti-NFIL3) control antibodies. Input indicates non-immunoprecipitated cell lysates. JC12 
blotting; top arrow indicates FOXP1FL, bottom arrow indicates FOXP1s (C). Co-immunoprecipitated FOXP2 was detected by Western 
blotting the JC12 immunoprecipitated proteins with the FOXP2-73A/8 antibody (D).
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assembly [44]. There were no statistically significant GO 
terms that distinguished FOXP2-positive versus FOXP2-
negative GCB-DLBCL cases, and no GO terms from the 
upregulated gene lists (i.e. positively-associated with 
FOXP2 expression) that distinguished FOXP2-positive 
versus FOXP2-negative DLBCL or ABC-DLBCL cases. 
Analysis of genes negatively-associated with 
FOXP2 protein expression in ABC-DLBCL cases 
identified distinct GO terms and pathways (Figure 6A; 
Table S2). The biological processes most frequently 
identified were those associated with T-cell receptor 
(TCR) signaling, immune responses and cell activation. 
Table 4: Correlation between FOXP2 and other markers as continuous variables
Marker
FoXP2
Pearson correlation P-value
CD10 −0.0326 0.6854
BCL6 −0.0878 0.2745
GCET1 −0.1815 0.0229
HIP1R −0.1083 0.1768
MUM1/IRF4 0.1584 0.0476
FOXP1 0.1259 0.1162
BLIMP1 0.1090 0.1727
HLA-DRA –0.0616 0.4420
Table 3: Correlation between FOXP2 and other markers as categorical variables
Marker & cut-off value
FoXP2
P-value
≥ 20% ≥ 20%
CD10
< 30% 73 14
0.7542
≥ 30% 60 10
BCL6
< 30% 16 4
0.5128
≥ 30% 117 20
GCET1
< 60% 78 18
0.1303
≥ 60% 55 6
HIP1R
≤ 10% 33 11
0.0348
> 10% 100 13
MUM1/ 
IRF4
< 30% 67 5
0.0075
≥ 30% 66 19
FOXP1
< 70% 62 5
0.0187
≥ 70% 71 19
BLIMP1
< 40% 112 18
0.3820
≥ 40% 22 6
HLA-DRA
< 90% 38 8
0.6213
≥ 90% 96 16
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Individual genes involved in TCR signaling and immune 
responses were downregulated in ABC-DLBCL with 
FOXP2 protein expression and showed a significantly 
inverse relationship with FOXP2 transcript expression 
(P < 0.0001; Figure 6B). In contrast, in GBC-DLBCL 
the same genes showed no correlation with either FOXP2 
protein or transcript expression, consistent with the 
absence of immune response and TCR-signaling GO 
pathways distinguishing FOXP2-positive versus -negative 
GCB-DLBCL. 
dIscussIon
There are a number of studies implicating FOXP2 
in human malignancy. The first, from our laboratory, 
described the high frequency expression of FOXP2 
in malignant plasma cells in multiple myeloma [43]. 
Among prostate cancers both loss and strong expression 
of FOXP2 was reported. Strong FOXP2 expression was 
associated with increased early risk of PSA (prostate-
specific antigen) recurrence in ERG (ets-related gene) 
fusion-negative tumors [45]. In breast cancer a network of 
microRNAs (particularly miR-199a), whose expression is 
deregulated by mesenchymal stem/stromal cells, repress 
FOXP2 expression. FOXP2 silencing in breast cancer 
promoted cancer stem cells and tumor metastasis, while 
elevated miR-199a and reduced FOXP2 expression 
correlated with a significantly inferior outcome for 
patients [46]. Downregulation of FOXP2 also correlated 
with poor survival in hepatocellular carcinoma patients 
and enhanced cell invasiveness, reducing the expression 
of E-cadherin and increasing that of vimentin [47]. There 
are parallels in the central nervous system where Foxp2 
and Foxp4 repress N-cadherin to regulate the integrity and 
cytoarchitecture of neuroepithelial progenitors [48]. Thus 
like many transcription factors including FOXP1, FOXP2 
may function as either an oncogene or tumor suppressor 
depending on cellular context.
The firmly established importance of FOXP1 in 
the pathogenesis of high-risk DLBCL and its partially 
overlapping functions with FOXP2 in normal tissues 
promoted us to investigate the expression patterns and 
clinical relevance of FOXP2 expression in DLBCL. Due 
to our interest in FOXP1 as a future therapeutic target 
in DLBCL we also aimed to determine whether FOXP2 
might function independently of FOXP1 or whether these 
Figure 5: Genes most highly-correlated with FOXP2 protein expression in primary DLBCL cases. (A–c) Top 20 genes 
positively- or inversely-correlated with FOXP2 protein positive expression in all DLBCL cases (n = 39; A), GCB-DLBCL (n = 24; B) or ABC-
DLBCL (n = 15; C) subtype. The cases were stratified according to FOXP2 protein positive (i.e. absolute positivity without regarding frequency 
cut-off) or negative (i.e. 0% frequency). FOXP2 protein was positive in six (of 24) GCB-DLBCL and five (of 15) ABC–DLBCL cases.
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transcriptional factors might be co-expressed and exhibit 
potential functional cooperativity. 
Analysis of DLBCL cell lines initially suggested 
that FOXP2 expression was restricted to ABC-DLBCL, 
with only two of six cell lines studied here (RIVA and 
SU-DHL-2) and another (OCI-Ly10) from a previous 
study [43], exhibiting levels of nuclear protein expression 
comparable to the JJN3 myeloma cell line. However, in 
primary DLBCL tumors similar frequency and intensity 
of FOXP2 protein expression was identified in both 
DLBCL COO subtypes, independently of whether the 
COO subtypes were defined by immunohistochemical 
algorithms or gene expression profiling. Despite 
common mechanisms inactivating BLIMP1 expression 
in ABC-DLBCL, a higher frequency expression of 
this transcription factor was still observed in non-GCB 
DLBCL in this series. The lack of relationship between 
full length FOXP2 protein expression and either an ABC/
non-GCB DLBCL subtype, or BLIMP1 expression, 
suggests that its expression in DLBCL is unlikely to reflect 
purely a plasmablastic tumor phenotype.
Here we show that FOXP2 is expressed in a 
subset of primary DLBCL tumors. Increased frequency 
of expression (≥ 20% nuclear positivity) or moderate 
to strong intensity FOXP2 protein expression both 
significantly correlated with poor OS and PFS in DLBCL 
patients treated with R-CHOP. FOXP2 expression 
identified patients with significantly inferior OS in both the 
GCB and non-GCB DLBCL subgroups and in multivariate 
analyses FOXP2 was a high-risk factor independently of 
both IPI and COO subtype. These data identify a novel 
role for FOXP2 in the pathogenesis of a subset of DLBCL.
There is currently little information regarding the 
biological roles of FOXP2 in normal B-cell differentiation 
or during the pathogenesis of hematological malignancies. 
FOXP2-positivity in DLBCL was associated with a distinct 
gene expression signature and GO pathways associated 
with regulation of cellular component organization, 
clathrin coat assembly and cellular component 
morphogenesis. Interestingly, the DAB2 gene, which is 
common to all three GO pathways, has been reported to 
be a putative tumor suppressor whose hypermethylation 
could contribute to activation of Wnt signaling in 
myeloma [49]. Analysis of the genetic heterogeneity in 
DLBCL using exome and whole genome sequencing has 
identified mutations in key biological pathways, including 
Figure 6: TCR signaling and immune response signatures were significantly reduced in FOXP2-positive ABC-DLBCL 
cases. (A) Gene ontology and pathway signatures suppressed in FOXP2-positive DLBCL cases compared with their FOXP2-negative 
counterparts. All DLBCL cases (n = 39) or ABC-DLBCL (n = 15) molecular subtype were analyzed separately. The bar graph was 
constructed on a negative log10 scale with higher -log10 value denoting more significant FDR value. The linear FDR values were shown 
next to or within each bar, and the horizontal dotted line denotes linear FDR threshold of 0.05. GO: Gene Ontology; PID: Pathway 
Interaction Database; RID: Reactome ID. (b) Heatmap visualization of genes involved in TCR and immune response signatures compared 
with FOXP2 microarray transcript expression (probe: 1555516_at) in FOXP2 protein positive or negative GCB-DLBCL (n = 24) or 
ABC-DLBCL (n = 15) cases. Line graphs comparing FOXP2 transcript expression with the averaged expression values of TCR/immune 
response genes (the region shaded in turquoise represents the standard deviation of the averaged values) were plotted corresponding to each 
case present on the heatmap.
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Wnt signaling [50]. Furthermore, FOXP1 has also been 
demonstrated to promote Wnt pathway signaling and 
sensitivity to Wnt inhibitors in DLBCL [33]. 
In FOXP2-positive ABC-DLBCL the down-
regulation of many biological processes associated with 
TCR signaling, immune responses and cell activation was 
particularly evident. These signatures were absent from 
FOXP2-positive GCB-DLBCL tumors. This suggests that 
FOXP2 may have overlapping or complimentary functions 
with FOXP1 in ABC-DLBCL, as FOXP1 silencing in 
ABC-DLBCL elevated immune response signatures 
and major histocompatibility class II expression [32, 
34]. Supporting evidence for some common functional 
relationships between FOXP1 and FOXP2 includes 
expression of the directly FOXP1 regulated gene HIP1R 
[23], which exhibited an inverse relationship with FOXP2 
expression in DLBCL at both the transcript and protein 
level.
While FOXP2 is co-expressed with FOXP1 in 
DLBCL, these two transcription factors generally show 
reciprocal patterns of protein expression in normal and 
malignant B cells. This mirrors findings in the CNS where 
only a partial overlap of FOXP1/FOXP2 expression is 
seen [51]. Thus it is possible that in some patients FOXP1/
FOXP2 dimers may regulate gene expression while in 
others FOXP1 or FOXP2 homodimers (or heterodimers 
with FOXP4) may regulate distinctly different patterns 
of gene expression. Further variables are provided by the 
expression of smaller FOXP1 isoforms in DLBCL [52] 
and our lack of knowledge regarding FOXP2 isoforms in 
this malignancy. In view of the importance of a blockade 
of plasma cell development in DLBCL, it is tempting to 
speculate that FOXP1 and FOXP2 expression patterns 
may define a particular and possibly transient stage of 
plasmablastic B-cell differentiation. Further studies are 
needed to identify patterns of FOXP2 isoform expression 
in DLBCL, define its contribution to DLBCL pathogenesis 
and potential functional cooperativity with FOXP1, 
and thus elucidate the mechanisms by which FOXP2 
expression contributes to poor outcome across DLBCL 
COO subtypes.
MATERIALS AND METHODS
Patient samples and cell lines 
Reactive tonsils were provided by the Oxford 
Radcliffe Biobank (Oxford, UK). DLBCL tissue 
microarrays (TMAs) have been described previously, 
and comprise duplicate 1.0 mm cores from a series of 
Danish patients who had been uniformly treated with 
R-CHOP with curative intent (n = 158) [53]. The clinical 
characteristics for all patients distributed according to 
either FOXP2 or BLIMP1 expression are provided in 
Table 1. Informed consent was obtained from all patients 
in accordance with the Declaration of Helsinki, and local 
ethical approval was obtained from the Oxfordshire 
Research Ethics Committee South Central-Oxford B 
(CO2.162). DLBCL cell lines were sourced as described 
previously [43, 52] and are regularly immunophenotyped 
and shown to be mycoplasma free. Cells were maintained 
in RPMI1640 media (Life Technologies, Paisley, UK) 
supplemented with 10% fetal calf serum, 2 mM glutamine 
at 37°C and 5% CO2.
FOXP2 quantitative reverse-transcription 
polymerase chain reaction (qRT-PCR) 
Total RNA extracted from DLBCL cell lines using the 
RNeasy kit (Qiagen, Crawley, UK) was reverse transcribed 
using random primers (Promega, Southampton, UK) 
and Superscript III reverse transcriptase 
(Life Technologies). Real-time PCR analysis was 
performed using a Chromo 4 continuous fluorescence 
detector (MJ Research, Waltham, MA, USA). Express 
qPCR supermix (Life Technologies) and a FOXP2 TaqMan 
pre-verified probe (Hs00362817_m1; Applied Biosystems, 
Warrington, UK) were used to amplify FOXP2 transcripts. 
Relative gene expression was normalized according to the 
expression of 18S rRNA (4319413E; Applied Biosystems) 
using the formula 2−ΔΔC(t).
FOXP2 Western blotting
Nuclear extracts from DLBCL cell lines were 
prepared using commercial reagents (Affymetrix, High 
Wycombe, UK). Proteins were resolved by gradient SDS-
PAGE (NuPAGE, Life Technologies) and transferred to 
an Amersham™ Protran Premium 0.45 µm nitrocellulose 
membrane (GE Healthcare, Chalfont St Giles, UK). The 
membrane was blocked for 1 h with 5% fat-free milk 
powder in PBS, before incubation overnight with primary 
antibody, FOXP2-73A/8 antibody or JC12 (both used 
at a 1/30 dilution of ‘in house’ hybridoma supernatant). 
After washing, the membrane was incubated with 1/5000 
dilution of horseradish peroxidase conjugated secondary 
antibody (Dako, Ely, UK). Labeling was detected using 
enhanced chemiluminescence reagent (GE Healthcare). 
Blots were re-probed with nucleophosmin (NA24, 
undiluted ‘in house’ hybridoma supernatant) to confirm 
adequate sample loading.
Immunohistochemistry (IHC) 
IHC labeling of the DLBCL TMAs for FOXP1, 
HIP1R, HLA-DRA and COO markers has been described 
previously [23, 34]. For the FOXP2 and BLIMP1 staining, 
paraffin-embedded slides were dewaxed prior to antigen 
retrieval in 50 mM Tris/2 mM EDTA (pH 9). FOXP2 
staining was performed by incubation overnight with a 
1/1000 dilution of the ‘in house’ FOXP2-73A/8 hybridoma 
supernatant at 4°C. Staining for BLIMP1 was performed 
Oncotarget52953www.impactjournals.com/oncotarget
for 30 minutes at room temperature using a 1/40 dilution 
of hybridoma supernatant from the mouse monoclonal 
anti-BLIMP1 clone ROS195G (Dr. Giovanna Roncador, 
CNIO, Madrid, Spain). Detection was performed with the 
NovoLink polymer system according the manufacturer’s 
instructions (Novocastra, Leica Microsystems, Milton 
Keynes, UK) and detected using an EnVision kit according 
to the manufacturer’s instructions (DakoCytomation, 
Denmark). Tonsil tissue was used as a positive control 
for immunolabeling and to confirm BLIMP1 and FOXP2 
labeling patterns were consistent with those previously 
reported. In particular, the absence of FOXP2 expression 
in normal lymphoid cells confirmed the lack of cross-
reactivity with FOXP1.
FOXP2 and BLIMP1 nuclear expression were 
independently scored by A.H.B/L.L and E.J.S, who were 
blinded to patient outcome and clinical characteristics. 
The non-nuclear 73A/8 staining observed in a small 
number of cases was not scored. A qualitative score was 
generated using a score of 3 for the strongest intensity of 
staining with 2 = moderate, 1 = weak and 0 = no labeling; 
when heterogeneity of intensity was observed within a 
core the stronger expression was scored, as long as this 
was present in more than a small minority of cells. A 
quantitative score was generated for tumor cell positivity 
in 10% increments. Discrepant scoring was resolved by 
joint review using a multi-headed microscope. Differences 
in intensity and frequency between duplicate cores were 
averaged and rounded up to the nearest intensity score or 
10% frequency. 
co-immunoprecipitation 
RIVA cell lysate (100 µg), prepared using RIPA 
buffer, was incubated separately with 20 µl of anti-FOXP1 
(JC12, hybridoma supernatant), 20 µl of anti-NFIL3 
(130/B4, “in house” hybridoma supernatant), or 2 µg 
of non-specific mouse IgG2a isotype (Dako, Ely, UK) 
antibody at 4°C for 2 h on a rotating wheel. 50 µl of µM 
ACS Protein G MicroBeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany) was added into each sample and 
rotated for a further 1 h at 4°C. Each lysate was then 
loaded onto a microcolumn (Miltenyi Biotec) and washed 
four times with 200 µl RIPA buffer. After one wash with 
low-salt wash buffer (50 mM NaCl, 20 mM Tris-HCl 
[pH 7.5], 2 mM EDTA, 1 × PIC, 1xPhos-STOP), 50 µl 
of pre-heated (95°C) 1 × SDS gel loading buffer was 
added and the eluate was collected in a fresh collection 
tube. The eluates were analyzed by Western blotting using 
anti-FOXP1 (JC12) or anti-FOXP2 (73A/8) antibodies as 
described above. A sample of the original RIVA lysate was 
included as the ‘input’.
Microarray data analysis
A total of 39 DLBCL cases derived from the 
TMA series (n = 158) studied here were previously gene 
expression profiled (GSE31312) [28]. Differentially 
expressed genes (DEGs), analyzed by using the GEO2R 
platform available on Gene Expression Omnibus and 
P ≤ 0.01 threshold used to determine significance, were 
obtained by comparing FOXP2 protein-positive versus 
FOXP2 protein-negative samples separately within three 
groups of cases: (1) All DLBCL cases (n = 39); (2) GCB-
DLBCL (n = 24); (3) ABC-DLBCL (n = 15). This resulted 
in two lists of DEGs for each group of cases comprising 
of up- or downregulated genes in FOXP2-positive versus 
FOXP2-negative DLBCL (Table S1). The 100 genes 
exhibiting the most significant difference in expression 
within each list were used for Gene Ontology (GO) and 
pathway enrichment analyses using the ToppGene Suite 
(https://toppgene.cchmc.org/) (Table S2). 
statistical analysis
Categorical and continuous variables were compared 
using chi-square and Mann-Whitney U tests, respectively, 
and Pearson correlation was used to determine association 
between two variables (GraphPad Prism v6.05; La Jolla, 
CA, USA). Survival analyses were conducted using the 
Kaplan-Meier method and compared using the log-rank 
test. Multivariate analysis was performed by comparing 
IPI ≥ 3 or non-GCB DLBCL subtype group of cases 
versus the cohort with FOXP2 ≥ 20% expression (SPSS 
Statistics v22; Chicago, IL, USA). A two-sided P-value of 
<0.05 determined statistical significance in all analyses.
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